Polen Capital's Q4 2025 Growth Portfolio: Performance & Activity

Polen Capital 54 Follower s Comments Summary Eli Lilly’s stock price has underperformed this year, much of it on the back of drug pricing concerns, potential tariff impacts and, perhaps, less enthusiasm for GLP-1 drugs. The primary drag for the quarter was Oracle, accounting for almost all of the Portfolio’s relative underperformance in Q4, completely reversing its performance from the prior quarter and giving back all of the gains experienced in Q3. Polen Capital initiated a 2.25% position in Intuitive Surgical who maintain a de facto monopoly in soft tissue robotic surgery globally. Polen Capital exited its position in Workday as the company’s revenue growth continues to decelerate. Polen Capital also sold its position in Netflix after the company agreed to acquire Warner Brothers (minus Discovery Global) for $83 billion. The following segment was excerpted from the Polen Focus Growth Portfolio Q4 2025 Commentary. Performance & Attribution In Q4 2025, the Portfolio returned -1.4% compared to +1.1% for the Index. Top relative contributors to the Portfolio’s performance included Eli Lilly ( This article was written by 54 Follower s Polen Capital is a global leader in quality growth and high yield investing. For over 30 years, Polen Capital has demonstrated an unwavering commitment to its clients, the community and each other. Polen Capital delivers distinctive growth and income solutions, building high conviction concentrated, competitively advantaged, active portfolios with the potential to compound and outperform over the long term. Note: This account is not managed or monitored by Polen Capital, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use Polen Capital's official channels. Comments